News Novo Holdings co-leads $200m financing into Esco Lifescience... Life sciences tools company Esco Lifesciences Group has scored $200m in a series A and crossover round co-led by Novo Holdings and
News Sobi plans filings for gout drug after phase 3 readout SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK